Drug Discovery
Bringing a new drug into the market, from the first step to the final market introduction, is a time consuming, highly regulated, and expensive process, which can take a decade or more. Final success crucially depends on the early availability of accurate analytical results, fast enough for taking the right decisions at the beginning of the development, and minimizing late attrition rates.
托托ay’s drug development is mainly based on a rational approach where typically establishing thebiological target焦点是第一个关键步骤。该目标识别需要对候选人的特性有深入的了解，以识别最有前途的属性，尽可能快速可靠。蛋白质及其配体的生物相互作用和相关性需要对结构和亲和力相关的方面进行见解 - 所有这些因素都被布鲁克（Bruker）在核磁共振中的广泛投资组合所涵盖（NMR), mass spectrometry (MS), single-crystal X-ray diffraction (SC-XRD), small-angle X-ray scattering (SAXS) and surface plasmon resonance (SPR). In many cases, preclinical imaging delivers important upfront information if a potential target elicits a biological response that might deem to modulate the disease.
Once a biological target has been established, finding the most promising lead molecules is often seen as the next challenge. Typically,lead discovery是潜在药物候选物的鉴定 - 小有机分子或具有治疗潜力的生物组件。
Rational drug design starts with the knowledge of the molecular structure of the target or reported active ligands. Both computational and empirical knowledge can be used to perform structure or ligand-based drug design (SBDD and LBDD, respectively). These approaches may be characterized by a comparably lower throughput requirement, but higher data density, e.g. about selectivity or the binding mode simultaneously. NMR, MS, SPR, Small-angle X-ray scattering (SAXS), and single-crystal X-ray diffraction (SC-XRD ) are techniques to mention here in the first place.
As the ongoing drug discovery process is time-sensitive, high throughput instrumentation with superior uptime, data quality, and assay flexibility is critical for success.Lead optimizationrequires advanced techniques allowing to investigate protein-ligand interactions from different perspectives at high data quality, yet with less throughput. The daily analytical support required for fast and successful medicinal chemistry is efficiently provided by our NMR, MS, SC-XRD solutions, and the combination of those. Whenever, throughout the entire drug discovery process, questions related to the details of thestructure analysisare addressed, these methods deliver the high-quality answers, indispensable and in-time.
托托ay, efficient drug discovery includes detailed studies to understandADME-Toxicity(absorption, distribution, metabolism, excretion, toxicity) at an early stage. We have developed dedicated toolboxes for our NMR, and MS solutions helping scientists to gain insight faster, avoid later phase failures, and comply with the most recent regulations.
Accelerating decision-making and building confidence inefficacy of treatment can be achieved faster in the drug discovery process using modernpreclinical imagingsolutions. Our solutions for animal MRI and microCT are setting the industrial standards and help to maximize the insights and consequently to minimize the number of test animals required.
